Active Ingredient(s): Ivosidenib
FDA Approved: * July 20, 2018
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Tibsovo Overview

Ivosidenib, sold under the brand name Tibsovo, is a medication for the treatment of acute myeloid leukemia (AML). It is a small molecule inhibitor of isocitrate dehydrogenase-1 (IDH1), which is mutated in several forms of cancer. The drug is being developed by Agios Pharmaceuticals and is in phase III clinical trials.[when?] The U.S. Food and Drug Administration (FDA) awarded orphan drug designation for acute myeloid leukemia and cholangiocarcinoma.[1][...

Read more Tibsovo Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Ivosidenib

Recent Tibsovo Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Tablet: 250mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Tibsovo: (1 result)

Sorted by National Drug Code
  • 71334-100 Tibsovo 250 mg Oral Tablet, Film Coated by Agios Pharmaceuticals, Inc.

Other drugs which contain Ivosidenib or a similar ingredient: (1 result)